

World Congress on
**NOVEL TRENDS AND ADVANCES IN BIOTECHNOLOGY,
CELL & STEM CELL RESEARCH &**
Joint Event On
15TH ANNUAL CONGRESS ON PEDIATRICS
November 28-29, 2018 Barcelona, Spain

RegenerAge System: Therapeutic effects of combinatorial biologics (mRNA and allogenic MSCs) with a spinal cord stimulation system on a patient with spinal cord section

Joel I Osorio¹, Sergei Paylian² and Ale Ismael González Cazares³

¹RegenerAge SAPI de CV, Mexico

²Bioquark Inc., USA

³Alive MD. Mexico

Bioquantine[®] a mRNA extract from *Xenopus laevis* frog oocytes (purified from intra- and extra-oocyte liquid phases of electroporated oocytes), showed potential as a treatment for a wide range of conditions in animal models, including Spinal Cord Injury (SCI) and Traumatic Brain Injuries (TBI) among others. The current study observed beneficial changes with Bioquantine[®] administration in a patient with severe SCI. Pluripotent stem cells have therapeutic and regenerative potential in clinical situations CNS disorders. One method of reprogramming somatic cells into pluripotent stem cells is to expose them to extracts prepared from *Xenopus laevis* oocytes. Due to ethical reasons and legal restrictions we selected a No Option patient, deciding to include in our protocol the RestoreSensor SureScan to complete it. Based on the electrical stimulation for rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan, we designed an improved delivery method for the *in-situ* application of MSCs and Bioquantine[®] in combination with the RestoreSensor[®] SureScan[®]. To the present day the patient who suffered a complete section of spinal cord at T12-L1 shows an improvement in sensitivity, strength in striated muscle and smooth muscle connection, 14 months after the first Bioquantine[®] and MSCs treatment and 9 months after the placement.

drosorio@regenerage.clinic

Notes: